ArticlePreventive medicine reports2026
Screening and diagnosis of gestational diabetes mellitus in routine antenatal care: A retrospective analysis from western Kazakhstan.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess gestational diabetes mellitus (GDM) diagnosis and screening practices in routine antenatal care in Kazakhstan. Methods: A retrospective cross-sectional study used electronic medical records of pregnant women receiving antenatal care in public outpatient clinics in Aktobe and Uralsk, Kazakhstan, from August 2024 to May 2025. Data were extracted from the DamuMed electronic medical system. A total of 445 pregnant women were included, of whom 229 had at least one GDM risk factor. Descriptive statistics and chi-square tests were used to assess screening practices and factors associated with oral glucose tolerance test (OGTT) performance at 24-28 weeks of gestation. Results: Fasting plasma glucose levels of 5.1-6.9 mmol/L were identified in 22.02% of women, while 1.57% had levels ≥7.0 mmol/L. However, GDM was documented in only 1.12%. Overall, 51.46% of women had at least one GDM risk factor. Among these women, 27.07% underwent OGTT at 24-28 weeks of gestation and 12.66% received an endocrinology consultation. OGTT uptake was significantly associated with elevated fasting plasma glucose, obesity, and a history of fetal macrosomia ( Conclusions: GDM screening and diagnosis appeared suboptimal, suggesting potential underdiagnosis and gaps in implementing national recommendations. Strengthened screening and referral pathways are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.